Voya Investment Management LLC purchased a new position in shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,487 shares of the biotechnology company’s stock, valued at approximately $101,000. Voya Investment Management LLC owned approximately 0.06% of Conatus Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Conatus Pharmaceuticals by 2.1% during the first quarter. Bank of New York Mellon Corp now owns 80,310 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 1,655 shares during the period. FNY Partners Fund LP lifted its holdings in shares of Conatus Pharmaceuticals by 98.0% during the second quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 9,800 shares during the period. Bank of Montreal Can bought a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $109,000. State of Wisconsin Investment Board bought a new position in shares of Conatus Pharmaceuticals in the second quarter valued at about $115,000. Finally, Airain ltd raised its holdings in shares of Conatus Pharmaceuticals by 244.4% in the second quarter. Airain ltd now owns 35,480 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 25,179 shares during the last quarter. 34.06% of the stock is owned by institutional investors.

Several equities analysts have recently issued reports on CNAT shares. Seaport Global Securities restated a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $10.00 price objective on shares of Conatus Pharmaceuticals in a research report on Thursday, August 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $16.00.

Conatus Pharmaceuticals Inc. (NASDAQ CNAT) opened at $4.15 on Friday. Conatus Pharmaceuticals Inc. has a 12-month low of $1.73 and a 12-month high of $9.40. The company has a quick ratio of 2.69, a current ratio of 2.69 and a debt-to-equity ratio of 0.41.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The company had revenue of $9.57 million for the quarter, compared to the consensus estimate of $16.06 million. During the same quarter in the prior year, the company earned ($0.31) EPS. sell-side analysts anticipate that Conatus Pharmaceuticals Inc. will post -0.65 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “17,487 Shares in Conatus Pharmaceuticals Inc. (CNAT) Acquired by Voya Investment Management LLC” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/17487-shares-in-conatus-pharmaceuticals-inc-cnat-acquired-by-voya-investment-management-llc/1725117.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Want to see what other hedge funds are holding CNAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT).

Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.